news
FDA's AI guidance sparks confusion among biopharma companies
Tala Fakhouri, a former AI regulator now in industry, says biopharma firms are misinterpreting the FDA's AI guidance by being too cautious. She argues the FDA should offer clearer directives to help companies innovate without unnecessary fear of non-compliance. This highlights ongoing tension in how quickly cutting-edge tech can integrate into regulated health sectors.
Tala Fakhouri, a former AI regulator now in industry, says biopharma firms are misinterpreting the FDA's AI guidance by being too cautious. She argues the FDA should offer clearer directives to help companies innovate without unnecessary fear of non-compliance. This highlights ongoing tension in how quickly cutting-edge tech can integrate into regulated health sectors.
The architecture take
The FDA's trying to keep pace with AI, but the messaging is muddy. This means companies building health-focused AI are likely leaving genuine innovation on the table simply because they're scared of a regulatory slap. Clearer guidelines would unlock a lot of potential here.